Risk factors for the development of postoperative complications in patients with metastatic kidney cancer treated with cytoreductive nephrectomy.

BACKGROUND: The role of cytoreductive nephrectomy on the treatment of metastatic renal cell carcinoma (mRCC) is controversial due to its high complexity. OBJECTIVE: To identify risk factors associated to postoperative complications in patients with mRCC after cytoreductive nephrectomy. METHOD: We conducted a retrospective, observational study in 67 patients who underwent cytoreductive nephrectomy for the management of mRCC. Demographic, perioperative and clinicopathologic -characteristics were registered. Surgical complications were classified using the Clavien-Dindo system; major complications were those of grade 3 or higher. We performed a binary logistic regression analysis to identify risk factors associated with surgical complications. RESULTS: Mean age was 56 years (37-83). Symptoms were present in 58 patients (89.7%). Weight loss was the predominant symptom (50.8%). Mean tumor diameter was 10.8 cm (4.6-22.5 cm). The rate of postoperative complications was 65%; 21 patients (31.4%) had major complications. Risk factors were estimated blood loss > 500 ml (OR 44.5, CI 95% 2.51-789, p = 0.01) and tumor diameter > 10 cm (OR 17.9, CI 95% 1.2-273, p = 0.04). CONCLUSIONS: Cytoreductive nephrectomy is a good option in highly selected patients with mRCC. Our major complication rate was 31.4%. Risk factors associated were blood loss and tumor diameter.

ANTECEDENTES: El papel de la nefrectomía citorreductora como tratamiento del carcinoma de células renales metastásico (CCRm) es controversial debido a su alta complejidad. OBJETIVO: Identificar factores de riesgo para complicaciones posquirúrgicas en pacientes con CCRm tratados con nefrectomía citorreductora. MÉTODO: Estudio retrospectivo, observacional, de 67 pacientes tratados con nefrectomía citorreductora por CCRm. Se registraron las características demográficas, perioperatorias y clinicopatológicas. Las complicaciones posquirúrgicas fueron clasificadas con el sistema Clavien-Dindo (mayores aquellas de grado 3 o superior). Se realizó un análisis de regresión logística binaria para identificar factores de riesgo para complicaciones. RESULTADOS: La edad media fue de 56 años (rango: 37-83), y 58 pacientes (89.7%) presentaron síntomas, predominando la pérdida de peso (50.8%). El diámetro tumoral medio fue de 10.8 cm (rango: 4.6-22.5). Un 65% tuvo complicaciones posquirúrgicas; en el 31.4% fueron mayores. Los factores de riesgo asociados fueron el sangrado transoperatorio ≥ 500 ml (odds ratio [OR]: 44; intervalo de confianza del 95% [IC 95%]: 2.51-789; p = 0.01) y el diámetro tumoral > 10 cm (OR: 17.9; IC 95%: 1.2-273; p = 0.04). CONCLUSIONES: La nefrectomía citorreductora es una opción de tratamiento para pacientes estrictamente seleccionados. Nuestra tasa de complicaciones mayores fue del 31.4%. Los factores de riesgo asociados fueron el sangrado transoperatorio y el diámetro tumoral.

Short- and mid- term impact of tobacco smoking on donor renal function following living kidney donation at a tertiary referral hospital

Background: The negative impact of tobacco smoking on renal function has been widely studied. However, there is limited knowledge about the effect of smoking on pre-operative and post-operative renal function in living kidney donors. Objective: The objective of the study was to evaluate the short- and mid-term impact of smoking on donor renal function. Methods: This is a retrospective study of 308 patients who underwent living donor nephrectomy (LDN) at a tertiary referral hospital. We compared baseline characteristics as well as functional outcomes following LDN according to history of tobacco smoking. Estimated glomerular filtration rate (eGFR) was calculated with the modification of diet in renal disease equation in 6 time periods: pre-operative, 1 week, 1 month, 6 months, 12 months, and 24 months after surgery. We performed a Kaplan-Meier analysis for chronic kidney disease (CKD) outcome and binary logistic regression analysis to identify risk factors associated with CKD at 24 months of follow-up. Results: Among donors, 106 (34.4%) reported a smoking history before nephrectomy. Smoking donors had worse pre-operative eGFR than non-smokers (90 ± 26.3 mL/min/1.73m2 vs. 96 ± 27 mL/min/1.73 m2, respectively; p = 0.02) and lower eGFR at 1 week (p = 0.01), 1 month (p ≤ 0.01), 6 months (p = 0.01), and 12 months (p = 0.01) after LDN. Tobacco smoking (OR 3.35, p ≤ 0.01) and age ≥ 40 years at donation (OR 6.59, p ≤ 0.01) were associated with post-operative development of CKD at 24 months after LDN. Conclusions: Living kidney donors with a tobacco smoking history had an increased risk of developing chronic kidney disease following nephrectomy. Smoking-cessation strategies should be implemented.

Short- and Mid-Term Impact of Tobacco Smoking on Donor Renal Function Following Living Kidney Donation at a Tertiary Referral Hospital.

BACKGROUND: The negative impact of tobacco smoking on renal function has been widely studied. However, there is limited knowledge about the effect of smoking on pre-operative and post-operative renal function in living kidney donors. OBJECTIVE: The objective of the study was to evaluate the short- and mid-term impact of smoking on donor renal function. METHODS: This is a retrospective study of 308 patients who underwent living donor nephrectomy (LDN) at a tertiary referral hospital. We compared baseline characteristics as well as functional outcomes following LDN according to history of tobacco smoking. Estimated glomerular filtration rate (eGFR) was calculated with the modification of diet in renal disease equation in 6 time periods: pre-operative, 1 week, 1 month, 6 months, 12 months, and 24 months after surgery. We performed a Kaplan-Meier analysis for chronic kidney disease (CKD) outcome and binary logistic regression analysis to identify risk factors associated with CKD at 24 months of follow-up. RESULTS: Among donors, 106 (34.4%) reported a smoking history before nephrectomy. Smoking donors had worse pre-operative eGFR than non-smokers (90 ± 26.3 mL/min/1.73m2 vs. 96 ± 27 mL/min/1.73 m2, respectively; p = 0.02) and lower eGFR at 1 week (p = 0.01), 1 month (p ≤ 0.01), 6 months (p = 0.01), and 12 months (p = 0.01) after LDN. Tobacco smoking (OR 3.35, p ≤ 0.01) and age ≥ 40 years at donation (OR 6.59, p ≤ 0.01) were associated with post-operative development of CKD at 24 months after LDN. CONCLUSIONS: Living kidney donors with a tobacco smoking history had an increased risk of developing chronic kidney disease following nephrectomy. Smoking-cessation strategies should be implemented.

Prostate cancer screening in low- and middle- income countries: the Mexican case / Tamizaje para cáncer de próstata en países de bajos y medianos ingresos: el caso mexicano

Abstract: Prostate-specific antigen (PSA)-based early detection for prostate cancer is the subject of intense debate. Implementation of organized prostate cancer screening has been challenging, in part because the PSA test is so amenable to opportunistic screening. To the extent that access to cancer screening tests increases in low- and middle-income countries (LMICs), there is an urgent need to thoughtfully evaluate existing and future cancer screening strategies to ensure benefit and control costs. We used Mexico's prostate cancer screening efforts to illustrate the challenges LMICs face. We provide five considerations for policymakers for a smarter approach and implementation of PSA-based screening.

Resumen : El uso del Antígeno Prostático Específico (APE) para tamizaje para cáncer de próstata sigue siendo tema de amplio debate. La implementación de estrategias de tamiz organizado de cáncer de próstata ha sido un reto en parte porque la prueba de APE se presta para detección oportunista. A medida que aumenta el acceso a las pruebas de detección de cáncer en los países de ingresos bajos y medianos (PIBM), existe la necesidad urgente de evaluar cuidadosamente las estrategias actuales y futuras de detección oportuna de cáncer para garantizar su beneficio y controlar sus costos. Utilizamos los esfuerzos de tamizaje de cáncer de próstata de México para ilustrar los retos para PIBM. Ofrecemos cinco consideracio nes dirigidas a tomadores de decisión que permitan contar con estrategias racionales de implementación de tamizaje para cáncer de próstata basado en el uso de APE.

Prostate cancer screening in low- and middle-income countries: the Mexican case.

Prostate-specific antigen (PSA)-based early detection for prostate cancer is the subject of intense debate. Implementation of organized prostate cancer screening has been challenging, in part because the PSA test is so amenable to opportunistic screening. To the extent that access to cancer screening tests increases in low- and middle-income countries (LMICs), there is an urgent need to thoughtfully evaluate existing and future cancer screening strategies to ensure benefit and control costs. We used Mexico's prostate cancer screening efforts to illustrate the challenges LMICs face. We provide five considerations for policymakers for a smarter approach and implementation of PSA-based screening.

El uso del Antígeno Prostático Específico (APE) para tamizaje para cáncer de próstata sigue siendo tema de amplio debate. La implementación de estrategias de tamiz organizado de cáncer de próstata ha sido un reto en parte porque la prueba de APE se presta para detección oportunista. A medida que aumenta el acceso a las pruebas de detección de cáncer en los países de ingresos bajos y medianos (PIBM), existe la necesidad urgente de evaluar cuidadosamente las estrategias actuales y futuras de detección oportuna de cáncer para garantizar su beneficio y controlar sus costos. Utilizamos los esfuerzos de tamizaje de cáncer de próstata de México para ilustrar los retos para PIBM. Ofrecemos cinco consideraciones dirigidas a tomadores de decisión que permitan contar con estrategias racionales de implementación de tamizaje para cáncer de próstata basado en el uso de APE.

Incidence and treatment of malignant tumors of the genitourinary tract in renal transplant recipients

ABSTRACT Purpose: To provide data of the incidence and management of common urological malignancies in renal transplant recipients. Materials and Methods: We conducted a retrospective analysis of a prospective database from August 1967 to August 2015. A descriptive analysis of the sample was performed. Results: Among 1256 consecutive RTR a total of 88 patients developed malignancies (7%). There were 18 genitourinary tumors in the 16 patients (20.45 % of all malignant neoplasms), incidence of 1.27%. The most common neoplasm encounter was renal cancer (38.8%), followed by urothelial carcinoma (33.3%). Median follow-up of transplantation was 197 months (R, 36-336). Mean time from RT to cancer diagnosis 89±70 months (R, 12-276). CsA and AZA was the most common immunosuppression regimen in 68.75%. Mean follow-up after diagnosis was 103±72 months (R 10-215). Recurrence free survival rate of 100%. Overall survival of 89.5% of the sample; there were two non-related cancer deaths during follow-up. Conclusions: The incidence of neoplasms in RTR was lower than in other series, with favorable functional and oncologic results after treatment. This suggests that actions to reduce the risk of these malignancies as well as a strict follow-up are mandatory for an early detection and treatment.

Incidence and treatment of malignant tumors of the genitourinary tract in renal transplant recipients.

PURPOSE: To provide data of the incidence and management of common urological malignancies in renal transplant recipients. MATERIALS AND METHODS: We conducted a retrospective analysis of a prospective database from August 1967 to August 2015. A descriptive analysis of the sample was performed. RESULTS: Among 1256 consecutive RTR a total of 88 patients developed malignancies (7%). There were 18 genitourinary tumors in the 16 patients (20.45% of all malignant neoplasms), incidence of 1.27%. The most common neoplasm encounter was renal cancer (38.8%), followed by urothelial carcinoma (33.3%). Median follow up of transplantation was 197 months (R, 36-336). Mean time from RT to cancer diagnosis 89±70 months (R, 12-276). CsA and AZA was the most common immunosuppression regimen in 68.75%. Mean follow-up after diagnosis was 103±72 months (R 10-215). Recurrence free survival rate of 100%. Overall survival of 89.5% of the sample; there were two non-related cancer deaths during follow up. CONCLUSIONS: The incidence of neoplasms in RTR was lower than in other series, with favorable functional and oncologic results after treatment. This suggests that actions to reduce the risk of these malignancies as well as a strict follow-up are mandatory for an early detection and treatment.

Prostate cancer.

Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. Age and family history are the main risk factors. The diagnosis is made by prostate biopsy in patients with abnormalities detected in their prostate-specific antigen (PSA) levels or digital rectal exam (DRE). This article reviews screening and diagnostic methods as well as treatment options for patients diagnosed with prostate cancer.

Prostate cancer / Cáncer de próstata

Abstract Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. Age and family history are the main risk factors. The diagnosis is made by prostate biopsy in patients with abnormalities detected in their prostate-specific antigen (PSA) levels or digital rectal exam (DRE). This article reviews screening and diagnostic methods as well as treatment options for patients diagnosed with prostate cancer.

Resumen El cáncer de próstata es el tumor más frecuente en hombres a nivel mundial, y de manera específica en México. Los principales factores de riesgo son la edad y la historia familiar. El diagnóstico se obtiene por medio de biopsia prostática en pacientes detectados por anormalidades en el antígeno prostático o tacto rectal. En este artículo se hace una discusión de los métodos de tamizaje, diagnóstico y opciones de tratamiento en pacientes con diagnóstico de cáncer de próstata.

Validation of the Spanish version of Ureteral Stent Symptom Questionnaire: prevalence of symptoms in a tertiary care center in Mexico.

OBJECTIVES: To develop and to validate the Spanish version of the Ureteral Stent Symptom Questionnaire (USSQ). Describe the prevalence of symptoms associated with the presence of ureteral stent in a Spanish-speaking population. METHODS: We developed and delivered the Spanish USSQ version to patients who underwent ureteral stent placement after endourological procedures. We determined the internal consistency and the instrument's sensitivity to change. Results of the patients were compared with a control group of healthy individuals. We analyzed the prevalence of symptoms in the six domains of the questionnaire and the overall quality of life. We compared the means of the results by gender to find significant differences in associated symptoms. RESULTS: We obtained good internal consistency values of the instrument. Significant differences were obtained after sensitivity to change analysis in the scores of all domains except sexual performance. The correlation between the domains of urinary symptoms, pain, and general health was high. The analysis of specific symptoms showed important affection in all domains, being more significant in urinary symptoms and pain. The ureteral catheter also affected the daily life and work performance. There were no significant differences when comparing the symptoms by gender or age. CONCLUSIONS: Spanish version of the USSQ is appropriate for assessing the symptoms associated with ureteral stent in the Spanish-speaking population. The ureteral catheter significantly affects the various aspects of life in this population.

[Comparison between surveillance, adjuvant radiotherapy, or salvage radiotherapy after radical prostatectomy in patients with prostate cancer (PCa) in stage pT3 or higher and/or positive surgical margins]. / Comparación entre vigilancia y radioterapia adyuvante o de salvamento después de una prostatectomía radical para cáncer de próstata (CaP) pT3 o con márgenes positivos.

OBJECTIVE: To assess the mid-term evolution of high-risk prostate cancer (PCa) initially treated with radical prostatectomy (RP) and to compare the role of surveillance and postoperative radiotherapy, either adjuvant (aRT) or salvage (sRT). METHODS: Retrospective study of 390 patients with PCa treated with RP at our institution from February 1988 to December 2012. Those in stage pT3 or higher and/or with positive surgical margins (PSM) were included. They were divided in three groups: group 1, undergoing surveillance after RP; group 2 receiving aRT; and group 3 receiving sRT. Cancer-specific survival (CSS) was estimated using the Kaplan-Meier method. RESULTS: 156 patients were analyzed. Mean age was 63.8 ± 6.9 years (45-79). Mean follow-up was 58 ± 45 months; 71 (45.5%) had PSM, 40 (25.6%) were in stage pT3 or higher, and 45 (28.8%) had both features. Group 1 included 91 patients, group 2, 43 and group 3, 22. Initial prostate-specific antigen (PSA) was 12.8 ng/ml in group 1, 14.9 ng/ml in group 2, and 14.5 ng/ml in group 3 (p = 0.07). First postoperative PSA was 0.27, 0.87, and 0.50 ng/ml in group 1, 2 and 3, respectively (p = 0.007). Seven men died of PCa: three in group 1, three in group 2, and one in group 3 (p = 0.6). The CSS at five and 10 years was 100 and 89% for group 1, 95 and 80% for group 2, and 94 and 94% for group 3 (p = 0.71). CONCLUSION: Our results retrospectively show that surveillance, aRT and sRT are equivalent for the mid-term control of PCa after RP.

[Surgical treatment of renal-cell carcinoma in von Hippel-Lindau disease]. / Tratamiento quirurgico del carcinoma de celulas renales en la enfermedad de von Hippel-Lindau.

OBJECTIVE: To describe the clinical outcome of surgical treatment of renal-cell carcinoma in patients with von Hippel-Lindau disease. To analyze the clinical, demographic and histopathological characteristics. MATERIAL AND METHODS: From a total of 468 patients with renal-cell carcinoma treated surgically at our institution from 1982 to 2010, a series of 8 with von Hippel-Lindau disease were identified. Relevant variables included tumor recurrence, surgical approach, recurrence rate and mid-term preserved renal function. RESULTS: Eight patients with von Hippel-Lindau disease and renal cell carcinoma were identified; 7 were treated with nephron-sparing surgery and 1 with radical nephrectomy. During the follow-up of 89.3 ± 67.5 months, we found ipsilateral tumor recurrence in two patients and contralateral in another one. Mean survival time was 72 months in seven out of eight patients who also preserved normal renal function; one patient with uncontrolled diabetes died from complications of chronic kidney disease five years after surgery. CONCLUSIONS: Nephron-sparing surgery offers acceptable oncologic and functional results for patients with renal cell carcinoma and Von Hippel-Lindau disease.

[Long-term renal function in patients with renal-cell carcinoma treated surgically: comparison between radical and partial nephrectomy]. / Función renal a largo plazo en pacientes con cáncer de células renales tratados quirúrgicamente: comparación entre nefrectomía radical y parcial.

PURPOSE: To compare the renal function (RF) in patients with renal-cell carcinoma (RCC) treated by radical (RN) or partial nephrectomy (PN) and to assess the impact of the two surgical techniques in the glomerular filtration rate (GFR). MATERIAL AND METHODS: We retrospectively analyzed the database of patients with renal tumors treated surgically. RF was assessed preoperatively and postoperatively and compared between both techniques. GFR was estimated using CKD-EPI formula. Statistical analysis included X2, Student's t and Friedman tests and a method of logistic regression (multivariate analysis). RESULTS: 223 patients with RCC, who underwent surgery between 1981 and 2010, had complete information. The mean follow-up was 67.6 +/- 49.6 months. There were no significant differences in baseline characteristics between the RN (n = 196) and PN (N = 27) groups. After 6 months a GFR < 60 mL/min/1.73 m2 was detected in 63% vs. 29% (p = 0.0007), after 12 months in 64% vs. 33% (p = 0.002) and after 60 months in 53% vs. 40% (p = 0.2) of the patients in RN and PN groups, respectively. The absolute decrease in GFR was 22% after RN and 17% after PN. In the multivariate analysis, preoperative GFR and type of surgery were associated with an impairment of RF after 6 and 12 months. CONCLUSION: RN results in a more important impairment of RF after 6 and 12 months. At 60 months, patients treated with PN maintain a mean GFR > 60 mL/min/1.73 m2.

[Hospital and organizational dynamics of the National Institutes of Health. Relationship with high-specialty hospitals]. / Dinámica hospitalaria y organizacional de los institutos nacionales de salud. Relación con los hospitales de alta especialidad.

In order to primarily encourage medical care, teaching and research activities in high specialty regional hospitals (HSRH), a number of strategies are explored to increase the number of patients cared for, improve the quality and timeliness of care and successfully integrate the function of these hospitals within the care and patient flow model expected by the Federal Government. These strategies include the use of information technology systems as platforms for telemedicine, including tele-imaging, tele-education and telepathology, thus fostering the quality and timeliness of medical care and narrow the relationship between these HSRH with the National Health Institutes. Other strategies such as extra-mural surgery, specific theme workshops, resident rotations, the use of simulators and "Science Weeks" are also explored so as to promote teaching and research. Finally, the reference and counter-reference system and the introduction of pension programs are evaluated as possible strategies supporting resource management.

[Surgical treatment of ureteropelvic junction obstruction]. / Estenosis ureteropiélica, tratamiento quirúrgico.

INTRODUCTION: Currently there are many therapeutic options for ureteropelvic junction obstruction (UPJO). Open pyeloplasty is the gold standard with a success rate of approximately 90%. We describe our experience in the treatment of UPJO. MATERIAL AND METHODS: We conducted a retrospective and descriptive study among our patients with UPJO surgically treated at the Department of Urology of our institution from 1970 to 2002. RESULTS: 126 UPJO were diagnosed in 114 patients. The most common symptoms at diagnosis were: pain in 105 patients (92.1), urinary tract infection (UTI) in 37 (32.4%) and hematuria in 24 (21%). The most common associated diseases were urolithiasis in 34 cases, crossing vessels in 10 and horseshoe kidney in 5. 123 procedures were undertaken: 92 (74.8%) dismembered pyeloplasties, 13 (10.7%) Foley Y-V pyeloplasties, in 8 (6.5%) release of crossing vessel, 5 (4%) endopyelotomies, 2 (1.6%) pyeloplasties Scardino-Prince, 2 patients with renal allograft in whom an anastomosis of renal pelvis to native ureter was performed and 1 (0.8%) ureter-ileal anastomosis in a patient with retroperitoneal fibrosis. The mean follow-up time was of 33.2 months. In 114 (92.7%) patients the procedure was successful. The overall complication rate was of 17.9% of which 2.4% were stricture recurrence associated with crossing vessels. CONCLUSION: Open dismembered pyeloplasty is the most common treatment procedure for UPJO at our institution. We report successful results, low morbidity, preservation of renal function and improving symptoms.

Estenosis ureteropiélica, tratamiento quirúrgico / Surgical treatment of ureteropelvic junction obstruction

Introducción: En la actualidad existen múltiples opciones de tratamiento para la estenosis ureteropiélica (EUP). La pieloplastia abierta es el estándar de oro, con una tasa de éxito mayor a 90%. El objetivo de este estudio es describir nuestra experiencia en el manejo quirúrgico de la EUP. Material y Métodos: Estudio retrospectivo y descriptivo de los casos de EUP manejados quirúrgicamente en el periodo comprendido entre 1970 y 2002. Resultados: Se diagnosticaron 126 EUP en 114 pacientes. Los principales síntomas fueron: dolor en 105 pacientes (92.1%), infección de vías urinarias en 37 (32.4%) y hematuria en 24 (21%). Las patologías asociadas con mayor frecuencia fueron: urolitiasis en 34 casos, cruce vascular en 10, y riñón en herradura en 5. Se realizaron 123 procedimientos: 92 (74.8%) pieloplastias desmembradas, 13 (10.7%) pieloplastias tipo Foley Y-V, en 8 (6.5%) sólo liberación de vasos anómalos o bridas, 5 (4%) endopielotomías, 2 pieloplastias tipo Scardino-Prince (1.6%), 2 pacientes transplantados (1.6%), con anastomosis de la pelvis del injerto al uréter nativo y una anastomosis ureteroileal (0.8%) en un paciente con fibrosis retroperitoneal. El tiempo promedio de seguimiento fue de 33.2 meses. En 114 pacientes (92.7%) el procedimiento fue exitoso. Se documentó 17.9% de complicaciones globales, 2.4% correspondió a reestenosis asociadas a cruce vascular. Conclusión: La pieloplastia desmembrada es el procedimiento más utilizado en pacientes con EUP con adecuados resultados, preservación de la función renal, mejoría de los síntomas y baja morbilidad.

INTRODUCTION: Currently there are many therapeutic options for ureteropelvic junction obstruction (UPJO). Open pyeloplasty is the gold standard with a success rate of approximately 90%. We describe our experience in the treatment of UPJO. MATERIAL AND METHODS: We conducted a retrospective and descriptive study among our patients with UPJO surgically treated at the Department of Urology of our institution from 1970 to 2002. RESULTS: 126 UPJO were diagnosed in 114 patients. The most common symptoms at diagnosis were: pain in 105 patients (92.1), urinary tract infection (UTI) in 37 (32.4%) and hematuria in 24 (21%). The most common associated diseases were urolithiasis in 34 cases, crossing vessels in 10 and horseshoe kidney in 5. 123 procedures were undertaken: 92 (74.8%) dismembered pyeloplasties, 13 (10.7%) Foley Y-V pyeloplasties, in 8 (6.5%) release of crossing vessel, 5 (4%) endopyelotomies, 2 (1.6%) pyeloplasties Scardino-Prince, 2 patients with renal allograft in whom an anastomosis of renal pelvis to native ureter was performed and 1 (0.8%) ureter-ileal anastomosis in a patient with retroperitoneal fibrosis. The mean follow-up time was of 33.2 months. In 114 (92.7%) patients the procedure was successful. The overall complication rate was of 17.9% of which 2.4% were stricture recurrence associated with crossing vessels. CONCLUSION: Open dismembered pyeloplasty is the most common treatment procedure for UPJO at our institution. We report successful results, low morbidity, preservation of renal function and improving symptoms.

[Bilateral radical nephrectomy and kidney transplantation as treatment for asynchronous bilateral renal cell carcinoma. A case report]. / Carcinoma de células renales bilateral asincrónico tratado con nefrectomía radical bilateral y transplante renal. Informe de un caso.

Bilateral renal cancer may require bilateral nephrectomy and chronic dialysis. However, an available option is kidney transplantation. Controversy exists about an adequate period of time to perform kidney transplantation and the role of immunotherapy on the risk of malignant recurrence. We report a case of bilateral asynchronous renal cell carcinoma treated with bilateral radical nephrectomy and kidney transplantation six years after without evidence of malignant disease.

Carcinoma de células renales bilateral asincrónico tratado con nefrectomía radical bilateral y transplante renal: informe de un caso / Bilateral radical nephrectomy and kidney transplantation as treatment for asynchronous bilateral renal cell carcinoma: a case report

El cáncer renal bilateral puede requerir nefrectomía bilateral y diálisis crónica. Sin embargo, una opción adecuada es el transplante renal. Aún existe controversia acerca del tiempo necesario para llevar a cabo el transplante y del papel de la terapia inmunosupresora en el riesgo de recurrencia. Presentamos un caso de cáncer renal bilateral asincrónico tratado con nefrectomía radical bilateral y transplante renal, después de 6 años sin actividad tumoral.

Bilateral renal cancer may require bilateral nephrectomy and chronic dialysis. However, an available option is kidney transplantation. Controversy exists about an adequate period of time to perform kidney transplantation and the role of immunotherapy on the risk of malignant recurrence. We report a case of bilateral asynchronous renal cell carcinoma treated with bilateral radical nephrectomy and kidney transplantation six years after without evidence of malignant disease.